Bionovo appoints David Boyle CFO
This article was originally published in Scrip
Executive Summary
Bionovo, a pharmaceutical company focused on the discovery and development of treatments for women's health and cancer, has appointed David Boyle senior vice-president and chief financial officer. He succeeds Thomas Chesterman, who is leaving the company to pursue other business interests. Mr Boyle was previously senior vice-president and CFO of AVI BioPharma, and vice-president of finance and CFO of XOMA.